Gastric and Gastroesophageal Junction Adenocarcinoma – Japan Drug Forecast and Market Analysis to 2024

Date: 2016-08

Gastric and Gastroesophageal Junction Adenocarcinoma – Japan Drug Forecast and Market Analysis to 2024


Gastric and gastroesophageal junction adenocarcinoma (G/GEJAC) represents the majority of gastric cancer cases worldwide. It is the fifth most diagnosed cancer globally, and the third most common cause of cancer death in the world. The major treatments for G/GEJAC are chemotherapy-based, but targeted therapies such as HER2 and angiogenesis inhibitors have been approved and are being added to chemotherapy regimens since 2010 and 2014, respectively.

Japan represented the largest gastric cancer market in the 8MM in 2014 due to the high numbers of incident cases and approved therapy options available. GlobalData expects the Japanese gastric cancer market to remain largest out of the 8MM; however, the lack of premium pricing opportunities in Japan is expected to limit market growth.

*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.


– Overview of G/GEJAC including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
– Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
– Sales forecast for the top drugs in Japan from 2014-2024.
– Analysis of the impact of key events as well the drivers and restraints affecting Japan G/GEJAC market.

Reasons to buy

– Understand and capitalize by identifying products that are most likely to ensure a robust return
– Stay ahead of the competition by understanding the changing competitive landscape for G/GEJAC.
– Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
– Make more informed business decisions from insightful and in-depth analysis of drug performance
– Obtain sales forecast for drugs from 2014-2024 in Japan.

Contact With Us
Join templatemonster at google+
Customized Research
Request Sample